| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | lipid binding | 9.84e-04 | 988 | 10 | 4 | GO:0008289 | |
| GeneOntologyMolecularFunction | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen | 4.01e-03 | 194 | 10 | 2 | GO:0016705 | |
| GeneOntologyBiologicalProcess | lipid transport | 6.68e-05 | 506 | 10 | 4 | GO:0006869 | |
| GeneOntologyBiologicalProcess | lipid localization | 1.03e-04 | 565 | 10 | 4 | GO:0010876 | |
| GeneOntologyBiologicalProcess | circadian rhythm | 1.94e-04 | 248 | 10 | 3 | GO:0007623 | |
| GeneOntologyBiologicalProcess | regulation of secretion | 3.93e-04 | 801 | 10 | 4 | GO:0051046 | |
| GeneOntologyBiologicalProcess | Fc receptor signaling pathway | 3.94e-04 | 62 | 10 | 2 | GO:0038093 | |
| GeneOntologyBiologicalProcess | lipid export from cell | 4.20e-04 | 64 | 10 | 2 | GO:0140353 | |
| GeneOntologyBiologicalProcess | rhythmic process | 5.78e-04 | 360 | 10 | 3 | GO:0048511 | |
| GeneOntologyBiologicalProcess | organelle localization by membrane tethering | 7.39e-04 | 85 | 10 | 2 | GO:0140056 | |
| GeneOntologyBiologicalProcess | membrane docking | 8.47e-04 | 91 | 10 | 2 | GO:0022406 | |
| GeneOntologyCellularComponent | organelle membrane contact site | 3.24e-04 | 57 | 10 | 2 | GO:0044232 | |
| GeneOntologyCellularComponent | cytoplasmic side of plasma membrane | 3.35e-03 | 185 | 10 | 2 | GO:0009898 | |
| GeneOntologyCellularComponent | cytoplasmic side of membrane | 5.12e-03 | 230 | 10 | 2 | GO:0098562 | |
| MousePheno | enlarged cerebellum | 1.72e-06 | 4 | 8 | 2 | MP:0008914 | |
| MousePheno | reduced long-term potentiation | 5.42e-05 | 141 | 8 | 3 | MP:0001473 | |
| MousePheno | decreased paired-pulse facilitation | 8.54e-05 | 25 | 8 | 2 | MP:0002920 | |
| MousePheno | abnormal long-term potentiation | 2.06e-04 | 221 | 8 | 3 | MP:0002207 | |
| MousePheno | increased stereotypic behavior | 3.89e-04 | 53 | 8 | 2 | MP:0001409 | |
| MousePheno | abnormal paired-pulse facilitation | 5.33e-04 | 62 | 8 | 2 | MP:0002918 | |
| Domain | C2_dom | 3.29e-03 | 164 | 10 | 2 | IPR000008 | |
| Pubmed | KDM5B Is Essential for the Hyperactivation of PI3K/AKT Signaling in Prostate Tumorigenesis. | 7.44e-08 | 2 | 10 | 2 | 32868382 | |
| Pubmed | JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate. | 1.56e-06 | 7 | 10 | 2 | 22753496 | |
| Pubmed | JNK1/2 represses Lkb1-deficiency-induced lung squamous cell carcinoma progression. | 2.68e-06 | 9 | 10 | 2 | 31089135 | |
| Pubmed | 4.09e-06 | 11 | 10 | 2 | 18322234 | ||
| Pubmed | Sox9 sustains chondrocyte survival and hypertrophy in part through Pik3ca-Akt pathways. | 2.41e-05 | 26 | 10 | 2 | 21367821 | |
| Pubmed | 1.49e-04 | 1049 | 10 | 4 | 27880917 | ||
| Interaction | RAB3GAP1 interactions | 3.42e-05 | 152 | 9 | 3 | int:RAB3GAP1 | |
| Interaction | CLCC1 interactions | 6.65e-05 | 190 | 9 | 3 | int:CLCC1 | |
| Interaction | RAB5C interactions | 8.70e-05 | 600 | 9 | 4 | int:RAB5C | |
| Interaction | LAMP2 interactions | 9.22e-05 | 609 | 9 | 4 | int:LAMP2 | |
| Interaction | ELL2 interactions | 9.29e-05 | 33 | 9 | 2 | int:ELL2 | |
| ToppCell | Fetal_brain-fetalBrain_Zhong_nature-GW08-Neuronal|GW08 / Sample Type, Dataset, Time_group, and Cell type. | 1.39e-04 | 80 | 10 | 2 | 5c39136f5f855efbf61e1f5348ea97ea2130b241 | |
| ToppCell | Control-Fibroblasts-Pericytes|Control / group, cell type (main and fine annotations) | 6.33e-04 | 171 | 10 | 2 | 080003f698f867935c2bfc55d241d3650f45a0ab | |
| ToppCell | facs-Thymus-nan-3m-Lymphocytic-DN4_thymocyte|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.41e-04 | 185 | 10 | 2 | d50406a9a5b8d75110ba5985741aa2293950c543 | |
| ToppCell | facs-Thymus-nan-3m-Lymphocytic-DN4_thymocyte|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.41e-04 | 185 | 10 | 2 | a2cae8c657e4f4d121476798e424876f7e247973 | |
| ToppCell | E18.5-Endothelial-Endothelial_blood-vessel-Microvascular_EC-CAP1|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 7.56e-04 | 187 | 10 | 2 | 3699d5e71d779da922920aa3160895db187bf81b | |
| ToppCell | E18.5-Endothelial-Endothelial_blood-vessel-Microvascular_EC-CAP1-CAP1_mature|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 7.56e-04 | 187 | 10 | 2 | 033ba52c0c2f9978784947098fa697368ae44834 | |
| ToppCell | 10x_3'_v2v3-Neoplastic-Stem-like-NPC-like-NPC-like_neural-C|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 7.65e-04 | 188 | 10 | 2 | e239bcdbd210a398a5850cb6fbf171d402f45a4f | |
| ToppCell | COVID_vent-Myeloid-Monocytic-SC_&_Eosinophil|COVID_vent / Disease condition, Lineage, Cell class and subclass | 7.73e-04 | 189 | 10 | 2 | 2157a2d40613f7d5ce2e7dbd266df441e449cdaf | |
| ToppCell | Smart-start-Cell-Wel_seq-Non-neoplastic-Vascular-Mural_cell-Pericyte|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 7.97e-04 | 192 | 10 | 2 | 09cb5b89a164ac7444774ccc8c90323c8ea2026b | |
| ToppCell | facs-Brain_Myeloid-Hippocampus-3m-Myeloid|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.05e-04 | 193 | 10 | 2 | 06b65110db974f4ef90d3511ff34428976a52c9c | |
| ToppCell | Smart-start-Cell-Wel_seq-Non-neoplastic-Vascular|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 8.05e-04 | 193 | 10 | 2 | 2ddf9b2770a0be9689e01d1a3d19e4a6d42c7a50 | |
| ToppCell | Smart-start-Cell-Wel_seq-Non-neoplastic-Vascular-Mural_cell|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 8.05e-04 | 193 | 10 | 2 | dd4bac8a93a5b9dcf7301f1d7d6e3eb6670f5c68 | |
| ToppCell | facs-Brain_Myeloid-Hippocampus-3m-Myeloid-microglial_cell|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.05e-04 | 193 | 10 | 2 | 9c16032bc03df8760ae199e8f19fdafa4c3f1827 | |
| ToppCell | facs-Brain_Myeloid-Hippocampus-3m|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.05e-04 | 193 | 10 | 2 | a4f91bca5eaa985982d33a528f7566ffde154d47 | |
| ToppCell | facs-Brain_Myeloid-Hippocampus-3m-Myeloid-nan|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.05e-04 | 193 | 10 | 2 | b39d7feaac4ff8f7409cd3d15e8f3c6391367275 | |
| ToppCell | Smart-start-Cell-Wel_seq-Non-neoplastic-Vascular-Mural_cell-Pericyte-G|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 8.22e-04 | 195 | 10 | 2 | d760d1423f9a8a373fe7b250ea9b1d67a0c0059f | |
| ToppCell | Smart-start-Cell-Wel_seq-Non-neoplastic-Vascular-Mural_cell-Scavenging_pericyte|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 8.30e-04 | 196 | 10 | 2 | cb61757646653f89faba503cb5d99e5dd5197b4c | |
| ToppCell | Smart-start-Cell-Wel_seq-Non-neoplastic-Vascular-Mural_cell-Scavenging_pericyte-G|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 8.30e-04 | 196 | 10 | 2 | 44e2df1b61e3819eae7e482bef0a733afe852d67 | |
| ToppCell | Control-Control-Others-HSPC|Control / Disease, condition lineage and cell class | 8.56e-04 | 199 | 10 | 2 | b71169be0d916b2ed139a3122d78bb154c71edb4 | |
| Drug | Hemin | 7.03e-06 | 90 | 10 | 3 | ctd:D006427 | |
| Drug | 1-methyl-4-phenylpyridinium | 2.88e-05 | 144 | 10 | 3 | CID000039484 | |
| Drug | veliparib | 3.99e-05 | 22 | 10 | 2 | ctd:C521013 | |
| Drug | NPS R-568 | 6.06e-05 | 27 | 10 | 2 | CID000158796 | |
| Drug | salvin | 1.41e-04 | 41 | 10 | 2 | ctd:C018381 | |
| Drug | gefitinib | 1.57e-04 | 255 | 10 | 3 | CID000123631 | |
| Drug | AC1O4QII | 1.63e-04 | 44 | 10 | 2 | CID006398468 | |
| Drug | 1tom | 2.19e-04 | 51 | 10 | 2 | CID000448763 | |
| Drug | Racemic mixture | 2.83e-04 | 58 | 10 | 2 | CID000365464 | |
| Drug | ethanol | 3.19e-04 | 837 | 10 | 4 | CID000000702 | |
| Drug | AC1L89QG | 3.89e-04 | 68 | 10 | 2 | CID000323970 | |
| Drug | dopamine quinone | 4.01e-04 | 69 | 10 | 2 | CID000162602 | |
| Drug | Benzene | 4.07e-04 | 892 | 10 | 4 | ctd:D001554 | |
| Drug | AM251 | 4.13e-04 | 70 | 10 | 2 | CID000002125 | |
| Drug | Rotenone | 5.77e-04 | 978 | 10 | 4 | ctd:D012402 | |
| Drug | rimonabant | 5.94e-04 | 84 | 10 | 2 | CID000104849 | |
| Drug | garlic oil | 5.94e-04 | 84 | 10 | 2 | CID000011617 | |
| Drug | 3-aminophenylboronic acid | 6.08e-04 | 85 | 10 | 2 | CID000092269 | |
| Drug | nogalonic acid methyl ester | 6.37e-04 | 87 | 10 | 2 | CID000443820 | |
| Drug | AG213 | 6.66e-04 | 89 | 10 | 2 | CID005328803 | |
| Drug | aniline | 7.12e-04 | 92 | 10 | 2 | ctd:C023650 | |
| Drug | Hydrochloric Acid | 7.43e-04 | 94 | 10 | 2 | ctd:D006851 | |
| Drug | levo-dromoran tartrate | 8.07e-04 | 98 | 10 | 2 | CID000003918 | |
| Drug | ticlopidine | 8.91e-04 | 103 | 10 | 2 | CID000005472 | |
| Drug | racemethorphan | 9.61e-04 | 107 | 10 | 2 | CID000003008 | |
| Drug | morphine hydrochloride | 1.01e-03 | 481 | 10 | 3 | CID000004253 | |
| Drug | HU-211 | 1.09e-03 | 114 | 10 | 2 | CID000107778 | |
| Drug | hydroxybutyrate | 1.11e-03 | 115 | 10 | 2 | CID000010413 | |
| Drug | 2-arachidonoylglycerol (2-AG | 1.19e-03 | 119 | 10 | 2 | CID000001541 | |
| Drug | 1c88 | 1.33e-03 | 126 | 10 | 2 | CID000444766 | |
| Drug | Asbestos, Crocidolite | 1.42e-03 | 1241 | 10 | 4 | ctd:D017638 | |
| Drug | ethylnylestradiol | 1.46e-03 | 1251 | 10 | 4 | CID000003285 | |
| Drug | carvedilol | 1.54e-03 | 136 | 10 | 2 | ctd:C043211 | |
| Drug | ethyl acetate | 1.57e-03 | 137 | 10 | 2 | CID000008857 | |
| Drug | mangiferin | 1.71e-03 | 143 | 10 | 2 | ctd:C013592 | |
| Disease | syndromic intellectual disability (implicated_via_orthology) | 9.90e-06 | 16 | 9 | 2 | DOID:0050888 (implicated_via_orthology) | |
| Disease | prostate cancer (is_marker_for) | 1.19e-05 | 156 | 9 | 3 | DOID:10283 (is_marker_for) | |
| Disease | Autistic Disorder | 5.53e-05 | 261 | 9 | 3 | C0004352 | |
| Disease | high grade glioma (is_implicated_in) | 7.08e-05 | 42 | 9 | 2 | DOID:3070 (is_implicated_in) | |
| Disease | Squamous cell carcinoma of the head and neck | 1.09e-04 | 52 | 9 | 2 | C1168401 | |
| Disease | Small cell carcinoma of lung | 1.17e-04 | 54 | 9 | 2 | C0149925 | |
| Disease | Dystonia | 2.98e-04 | 86 | 9 | 2 | C0013421 | |
| Disease | Reperfusion Injury | 3.19e-04 | 89 | 9 | 2 | C0035126 | |
| Disease | Adenocarcinoma of large intestine | 3.72e-04 | 96 | 9 | 2 | C1319315 | |
| Disease | urinary bladder cancer (is_marker_for) | 4.61e-04 | 107 | 9 | 2 | DOID:11054 (is_marker_for) | |
| Disease | breast cancer (is_implicated_in) | 9.03e-04 | 150 | 9 | 2 | DOID:1612 (is_implicated_in) | |
| Disease | autism spectrum disorder (implicated_via_orthology) | 9.27e-04 | 152 | 9 | 2 | DOID:0060041 (implicated_via_orthology) |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| EPVWEENFTFFIHNP | 581 | A0FGR8 | |
| FEELFPDWIFPSESE | 271 | P45984 | |
| VPFTHWFFSFVEDPL | 236 | Q8NEN9 | |
| WFFSFVEDPLIDFEV | 241 | Q8NEN9 | |
| EPSWEEFADPFAFIH | 36 | Q9UGL1 | |
| FVWFVVDPPHIIIDY | 711 | O00222 | |
| EAVWEKPFRFHPEHF | 406 | P10635 | |
| EFHWFIPTEFFVPEI | 341 | Q8NBW4 | |
| FHFWVNTFFIPGPEE | 271 | P60484 | |
| LEDVHIWIGVPFFFV | 26 | Q6IFG1 | |
| FIFEVPWCFFPKSVE | 111 | Q03403 |